Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 54, Issue 6

Issues

Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis

Peter Mollee
  • Corresponding author
  • Haematology Department, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, QLD 4102, Australia
  • Amyloidosis Centre, Princess Alexandra Hospital, Brisban, Australia; and School of Medicine, University of Queensland, Brisbane, Australia
  • School of Medicine, University of Queensland, Brisbane, Australia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Giampaolo Merlini
  • Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo
  • Department of Molecular Medicine, University of Pavia, Pavia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-01-14 | DOI: https://doi.org/10.1515/cclm-2015-0938

Abstract

The disease causing agent in systemic AL amyloidosis is a monoclonal immunoglobulin free light chain, or fragments thereof, circulating in the blood. It is not surprising, therefore, that measurement of serum free light chains plays a central role in the management of this disorder. In this paper, we review the utility of the serum free light chain assay in the investigation, prognostication and monitoring of AL amyloidosis. Data on the two currently available commercial assays is compared and some practical applications of the assay’s use are presented. While there are limitations, it is clear that the availability of the free light chain assay in the laboratory is a major advance and plays an essential role in the management of patients with AL amyloidosis.

Keywords: AL amyloidosis; free light chains; monitoring

References

  • 1.

    Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924–33.Google Scholar

  • 2.

    Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol 2014;32:2699–704.Web of ScienceGoogle Scholar

  • 3.

    Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 2013;83:463–70.Web of ScienceGoogle Scholar

  • 4.

    Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24.Web of ScienceGoogle Scholar

  • 5.

    Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol 2015;168:207–18.Google Scholar

  • 6.

    Weber N, Mollee P, Augustson B, Brown R, Catley L, Gibson J, et al. Management of systemic AL amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J 2015;45:371–82.Web of ScienceGoogle Scholar

  • 7.

    Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55:1517–22.Google Scholar

  • 8.

    Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009;55:499–504.Web of ScienceGoogle Scholar

  • 9.

    Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 2008;93:459–62.Web of ScienceGoogle Scholar

  • 10.

    Morris KL, Tate JR, Gill D, Kennedy G, Wellwood J, Marlton P, et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007;37:456–63.Web of ScienceGoogle Scholar

  • 11.

    Akar H, Seldin DC, Magnani B, O’Hara C, Berk JL, Schoonmaker C, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005;12:210–5.Google Scholar

  • 12.

    Mollee P, Tate J, Pretorius CJ. Evaluation of the N latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med 2013;51:2303–10.Web of ScienceGoogle Scholar

  • 13.

    Palladini G, Bosoni T, Milani P, Pirolini L, Foli A, Li Bergolis F, et al. Use of the novel monoclonal assay for the measurement of circulating free light chain in the diagnosis, prognostication of survival and assessment of response to therapy in AL amyloidosis. Paper presented at Annual Meeting of the Americal Society of Hematology December 10, 2012 Atlanta GA 2012.Google Scholar

  • 14.

    Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121:5124–30.Web of ScienceGoogle Scholar

  • 15.

    Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010;116:5126–9.Google Scholar

  • 16.

    Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378–83.Google Scholar

  • 17.

    Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009;94:380–6.Web of ScienceGoogle Scholar

  • 18.

    Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, et al. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia 2010;24:1498–505.Google Scholar

  • 19.

    Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78–84.Google Scholar

  • 20.

    Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–9.Web of ScienceGoogle Scholar

  • 21.

    Yoshida T, Matsuda M, Katoh N, Tazawa K, Shimojima Y, Gono T, et al. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. Internal Med 2008;47:1783–90.Web of ScienceGoogle Scholar

  • 22.

    Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319–24.Google Scholar

  • 23.

    Gertz MA, Kyle RA, Greipp PR. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood 1989;74:1108–11.Google Scholar

  • 24.

    Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003;101:827–30.Google Scholar

  • 25.

    Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–7.Google Scholar

  • 26.

    Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–95.Google Scholar

  • 27.

    Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in al. Blood 2006;107:3854–8.Google Scholar

  • 28.

    Perlini S, Musca F, Salinaro F, Fracchioni I, Palladini G, Obici L, et al. Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid 2011;18 (Suppl 1):96–7.Web of ScienceGoogle Scholar

  • 29.

    van G, II, van Rijswijk MH, Bijzet J, Vellenga E, Hazenberg BP. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009;94:1094–100.Web of ScienceGoogle Scholar

  • 30.

    Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011;86:251–5.Google Scholar

  • 31.

    Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317–25.Web of ScienceGoogle Scholar

  • 32.

    Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008;112:4009–16.Google Scholar

  • 33.

    Palladini G, Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A, et al. Al amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma 2009; 9:80–3.Web of ScienceGoogle Scholar

  • 34.

    Gertz MA, Buadi FK, Hayman SR. IgM amyloidosis: clinical features in therapeutic outcomes. Clin Lymphoma Myeloma Leuk 2011;11:146–8.Web of ScienceGoogle Scholar

  • 35.

    Wechalekar AD, Gillmore JD, Foard D, Rannigan L, Lane T, Pinney JH, et al. Evaluation of an early switch to second line chemotherapy in AL amyloidosis among patients who fail to achieve a very good partial response to frontline treatment. Presented at the XIIIth International Symposium on Amyloidosis Groningen, The Netherlands, 2012.Google Scholar

  • 36.

    Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay–analytical issues. Clin Biochem Rev 2009;30:131–40.Google Scholar

  • 37.

    Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376:30–6.Web of ScienceGoogle Scholar

  • 38.

    Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem 2012;49:450–5.Web of ScienceGoogle Scholar

  • 39.

    te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N latex FLC – new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323–32.Web of ScienceGoogle Scholar

  • 40.

    Mills JR, Barnidge DR, Murray DL. Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods 2015;81:56–65.Web of ScienceGoogle Scholar

  • 41.

    VanDuijn MM, Jacobs JF, Wevers RA, Engelke UF, Joosten I, Luider TM. Quantitative measurement of immunoglobulins and free light chains using mass spectrometry. Anal Chem 2015;87:8268–74.Web of ScienceGoogle Scholar

About the article

Corresponding author: Peter Mollee, Haematology Department, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, QLD 4102, Australia; Amyloidosis Centre, Princess Alexandra Hospital, Brisban, Australia; and School of Medicine, University of Queensland, Brisbane, Australia; and School of Medicine, University of Queensland, Brisbane, Australia


Received: 2015-09-28

Accepted: 2015-12-14

Published Online: 2016-01-14

Published in Print: 2016-06-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 54, Issue 6, Pages 921–927, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2015-0938.

Export Citation

©2016 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Ana Lopez de la Guia, Enrique Bengoechea, Luis Palomera, Felipe de Arriba, Jose Mariano Hernandez, Miquel Granell, Francisco Javier Peñalver, Ramon Garcia-Sanz, Juan Besalduch, Yolanda Gonzalez, Rafael Benigno Martinez, Miguel Teodoro Hernandez, Norma C. Gutierrez, Paloma Puerta, Antonio Valeri, Bruno Paiva, Joan Blade, Maria-Victoria Mateos, Jesus San Miguel, Juan Jose Lahuerta, Joaquin Martinez-Lopez, and Jianjun Zhao
PLOS ONE, 2018, Volume 13, Number 9, Page e0203392
[2]
S Sidana, N Tandon, A Dispenzieri, M A Gertz, F K Buadi, M Q Lacy, D Dingli, A L Fonder, S R Hayman, M A Hobbs, W I Gonsalves, Y L Hwa, P Kapoor, R A Kyle, N Leung, R S Go, J A Lust, S J Russell, S R Zeldenrust, S V Rajkumar, and S K Kumar
Leukemia, 2017
[3]
Paolo Milani, Giovanni Palladini, and Giampaolo Merlini
Scandinavian Journal of Clinical and Laboratory Investigation, 2016, Volume 76, Number sup245, Page S113

Comments (0)

Please log in or register to comment.
Log in